Potent Vaccine Could Beat Alzheimer's...
Added On : 16th November 2011
Potent Vaccine Could Beat Alzheimer's, But It Must Be Given Even Before There Are Any Symptoms, Say ScientistsThe secret to beating Alzheimer's disease, the most common form of dementia, could be as simple as a potent vaccine, scientists have discovered.
But the injection would need to be given at the earliest stages of the disease, before any of the symptoms of Alzheimer's are evident.
By preventing the disease from taking hold in the first place, researchers hope to pave the way to completely eradication.
However U.S. scientists still need to develop the vaccine, and to fine tune early detection of the disease.
Alzheimer's is a progressive, physical disease which affects the brain by destroying links between the cells.
Initial signs include forgetfulness, but it can lead to sufferers undergoing a complete personality change and being unable to talk or walk.
Researchers at Georgetown University, in Washington DC, found that an antibody for Alzheimers disease is more likely to trigger inflammation in the brain the later it is given.
The study adds to evidence that early intervention with any new antibody treatment is therefore likely to be important.
Researchers tested an antibody called PFA1 on mice that had been bred with Alzheimers symptoms.
The antibody was designed to clear amyloid, a protein that builds in the brains of people with the disease.
Although PFA1 reduced the amount of amyloid in the brain, mice that had more amyloid in their brains at the start of the study were more likely to show signs of inflammation after treatment.
Those with lower levels of amyloid - imitating humans in the early stages of the disease - did not experience the same level of swelling and showed a significant benefit from the vaccine.
The scientists presented their findings at the annual meeting of the Society for Neuroscience.
The research is significant both because it suggests that those in the early stages of the disease - with lower levels of amyloid - will benefit most from the vaccine.
It also give clues as to why inflammation happens.
The studys lead investigator, Dr R Scott Turner, said that patients often show no symptoms of inflammation.
Dr Turner said: 'Excessive inflammation is counter-productive because it will limit the benefits of the vaccine treatment, and in a few cases, will cause new problems.'
He added: 'We may find that in the future, we will have to tailor immunisation therapies based on amyloid burden in individual patients.'
Dr Simon Ridley, head of research at Alzheimers Research UK, said: 'This study adds to increasing evidence suggesting that an effective treatment for Alzheimers disease will need to be given early to have a positive effect.
'The value of a vaccine is dependent on the ability to identify people who are in the very early stages of the condition'
'Although this particular drug was not designed for use in people, we would need to see large-scale clinical trials before we can know whether any new drugs could benefit people with Alzheimers, and well need to test them early.
'We are still hamstrung by a lack of accurate early detection for Alzheimers, a major obstruction to trialling new treatments effectively.
'Research into diagnosis is crucial if potential new treatments are to have the best chance of success.
'We already know that inflammation may play a role in Alzheimers disease, and it will be important to follow this up.
'If we can understand what happens in the brain as Alzheimers progresses, we stand a better chance of being able to intervene.'
Dr Anne Corbett, of the Alzheimers Society, also welcomed the research, but warned that early detection of the disease was still very difficult.
She said: 'Finding a vaccine would be an exciting and life changing matter for people living with Alzheimers.
'However the value of a vaccine is dependent on the ability to identify people who are in the very early stages of the condition which alone is a challenge.
'This is very early research and we dont yet know if this vaccine could actually improve symptoms in humans.'
WHAT IS ALZHEIMER'S DISEASE?Alzheimer's disease is the most common form of dementia, which is a group of symptoms associated with a decline in mental abilities, such as memory and reasoning.
The disease attacks nerves, brain cells and neurotransmitters (chemicals that carry messages to and from the brain).
Early symptoms include:
minor memory problems
difficulty saying the right words
These symptoms change as Alzheimers, which is progressive, develops, and it may lead to:
confusion
personality changes
a total change in behaviour
Alzheimer's disease is most common in people over 65 years of age, and affects slightly more women than men.
The Alzheimers Society estimates that, in people over 65 years of age, 1 in 14 is affected by Alzheimers disease.
The risk increases with age, and people who are over 80 years of age are thought to have a one in six chance of developing the condition.